Trial Profile
Identifying Ocular and Systemic Biomarkers for Response to Aflibercept in Asian Patients With Centre Involving Diabetic Macular Edema: A Prospective Clinical Trial
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Biomarker; Therapeutic Use
- 18 Apr 2019 Status changed from not yet recruiting to recruiting.
- 10 Apr 2019 Planned number of patients changed from 100 to 36.
- 10 Apr 2019 Planned End Date changed from 1 Mar 2019 to 1 Mar 2021.